4-Methyl-2-nitro-1-phenoxybenzene | 2172-90-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Methyl-2-nitro-1-phenoxybenzene
• 英文别名: (4-methyl-2-nitro-phenyl)-phenyl ether；(4-Methyl-2-nitro-phenyl)-phenyl-aether；2-Nitro-4-methyl-diphenylether；4-Methyl-2-nitro-diphenylether；4-Methyl-2-nitrophenoxybenzol；4-Methyl-2-nitro-1-phenoxy-benzene
• CAS: 2172-90-9
• 化学式: C₁₃H₁₁NO₃
• 分子量: 229.235
• InChiKey: LPNFYHAPDYJTLP-UHFFFAOYSA-N

物化性质

• 沸点：
  185 °C(Press: 2.8 Torr)
• 密度：
  1.218±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-Methyl-2-nitro-1-phenoxybenzene 在 硝酸 作用下， 生成 (4-甲基-2-硝基-苯基)-(4-硝基-苯基)-醚
  参考文献：
  名称：

  16.被甲基-4'-硝基-和-4'-乙酰氨基-二苯基醚取代

  摘要：

  DOI：

  10.1039/jr9340000052
• 作为产物：
  描述：

  3-硝基-4-氯甲苯 、 苯酚 以35%的产率得到4-Methyl-2-nitro-1-phenoxybenzene
  参考文献：
  名称：

  An Improved Synthesis of Dibenzofurans by a Free-Radical Cyclization

  摘要：

  Reaction conditions for the formation of dibenzofurans from diazotized o-(aryloxy)anilines have been examined. Several promoters (hydroquinone, SnCl2, NaI, CuSO4, FeSO4, etc.) have been discovered; these act as electron donors and promote a free-radical mechanism. The best of these is FeSO4 which shortens the reaction time from hours to minutes and contributes to high yields (77-83%). We have been able to transform the cyclization to a reliable and convenient synthesis.

  DOI：

  10.1021/jo00121a016

文献信息

• 1-,2-,3-,4-,5-,6-,7-,8- and/or 9 substituted dibenzoxazepine compounds,
  申请人：G. D. Searle & Co.

  公开号：US05304644A1

  公开（公告）日：1994-04-19

  The present invention provides substituted dibenzoxazepine compounds of Formula I: ##STR1## which are useful as analgesic agents for the treatment of pain, pharmaceutical compositions comprising a therapeutically-effective amount of a compound of Formula I in combination with a pharmaceutically-acceptable carrier, and a method for eliminating or ameliorating pain in an animal comprising administering a therapeutically-effective amount of a compound of Formula I to the animal.

  本发明提供了一种公式I的取代二苯并噁唑啉化合物：##STR1##，其作为镇痛剂用于治疗疼痛，包括公式I化合物的治疗有效量与药用可接受载体结合的药物组合物，以及一种消除或改善动物疼痛的方法，包括向动物施用公式I化合物的治疗有效量。
• ANTI-VIRAL COMPOUNDS
  申请人：Rockway W. Todd

  公开号：US20070232645A1

  公开（公告）日：2007-10-04

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

  本发明揭示了有效抑制丙型肝炎病毒（“HCV”）或其他病毒复制的化合物。本发明还涉及包含这种化合物的组合物、与其他抗病毒或治疗剂一起配方或共同管理这种化合物的组合物、用于合成这种化合物的过程和中间体，以及使用这种化合物治疗HCV或其他病毒感染的方法。
• Anti-viral compounds
  申请人：Abbott Laboratories

  公开号：US07763731B2

  公开（公告）日：2010-07-27

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

  本发明揭示了一种有效抑制丙型肝炎病毒（“HCV”）或其他病毒复制的化合物。该发明还涉及包含这种化合物的组合物、与其他抗病毒或治疗剂共同配方或共同管理这种化合物的组合物、用于合成这种化合物的过程和中间体，以及使用这种化合物治疗HCV或其他病毒感染的方法。
• Anti-Viral Compounds
  申请人：Rockway Todd W.

  公开号：US20100256139A1

  公开（公告）日：2010-10-07

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

  本发明揭示了一些有效抑制丙型肝炎病毒（“HCV”）或其他病毒复制的化合物。本发明还涉及包含这些化合物的组合物，这些化合物与其他抗病毒或治疗剂的联合制剂或联合给药，用于合成这些化合物的过程和中间体，以及使用这些化合物治疗HCV或其他病毒感染的方法。
• Asymmetric hydrogenation of dibenzo-fused azepines with chiral cationic ruthenium diamine catalysts
  作者：Zi-Qi Yi、Bo-Wen Deng、Fei Chen、Yan-Mei He、Qing-Hua Fan

  DOI：10.1039/d3nj01652h

  日期：——

  Highly efficient asymmetric hydrogenation of dibenzo[b,f][1,4]oxazepine, dibenzo[b,f][1,4]thiazepine and dibenzo[b,e]azepine derivatives with chiral cationic ruthenium diamine catalysts has been developed, giving diverse chiral seven-membered N-heterocycles with excellent results (up to 99% yield and 99% ee). Moreover, it was found that the catalyst counteranion regulated the enantioselectivity obviously

  二苯并[ b , f ][1,4]恶氮、二苯并[ b , f ] [1,4]硫氮和二苯并[ b , e ]氮杂衍生物与手性阳离子二胺钌催化剂的高效不对称氢化反应已被开发出来，得到多样的手性七元 N-杂环化合物，具有优异的结果（高达 99% 的产率和 99% 的 ee）。此外，发现催化剂抗衡阴离子在二苯并[ b，f ][1，4]噻氮和二苯并[ b，e ]衍生物的加氢反应中明显调节对映体选择性。